ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Over the past two decades, three generations of Tyrosine Kinase Inhibitors (TKIs) have been developed to target the BCR::ABL1 oncoprotein to successfully treat chronic myeloid leukemia (CML).